Previous 10 | Next 10 |
3 Biotech Penny Stocks to Watch in Mid-November 2021 Biotech penny stocks remain some of the most popular stocks of the past year and a half. While the pandemic highlighted the biotech industry at first, we are still seeing the effects of this over one year after it began. But, not all ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips One of the big movers in today’s rather green market is Alzamend Neuro (NASDAQ: ALZN ). At the time of writing, ALZN stock has jumped more than 25% on extremely heavy volume. Of course, such a move is...
Shares of Alzamend Neuro (ALZN +28.2%) are up significantly today after one of the company's largest shareholders purchased an additional 100K shares. Milton C. Ault III now directly owns a total of 250K shares. Indirectly, Ault also own ~31.7M shares thorugh his roles in Ault Life Sciences, ...
Gainers: ReWalk Robotics (NASDAQ:RWLK) +37%, Ontrak (NASDAQ:OTRK) +35%, Alzamend Neuro (NASDAQ:ALZN) +32%, Chinook Therapeutics (NASDAQ:KDNY) +23%, Alimera Sciences (NASDAQ:ALIM) +22%. Losers: Deciphera Pharmaceuticals (NASDAQ:DCPH) -74%, Cali...
Protagonist Therapeutics (NASDAQ:PTGX) +89% after FDA removes clinical hold on rusfertide program Flexion Therapeutics (NASDAQ:FLXN) +73% Pacira Therapeutics acquires Flexion Therapeutics for $8.50 per share in cash plus one CVR Adamas Pharmaceuticals (NASDAQ:ADMS) +7...
Shares of Cassava Sciences (SAVA -6.2%) are down in afternoon trading after announcing this morning it was starting a phase 3 trial of simufilam for Alzheimer's disease. Shares traded up in premarket trading. Although shares are up more than 738% year-to-date, the stock has had a roller ...
Annovis Bio (NYSE:ANVS) gains 12% premarket after announcing results from the completed dose response Phase 2 clinical trial of ANVS401 in 54 Parkinson's disease (PD) patients, which found that once-daily ANVS401 was superior to placebo in improving motor function. Th...
Marine Petroleum Trust (NASDAQ:MARPS) +52%. U.S. Energy USEG +23% new assets to nearly quadruple production Annovis Bio (NYSE:ANVS) +16% announces positive phase 2 efficacy data for the treatment of parkinson's disease Team TISI +14% wins upstream mechanical insp...
Gainers: Alzamend Neuro (NASDAQ:ALZN) +44%. Farmmi (NASDAQ:FAMI) +31%. Paltalk (NASDAQ:PALT) +29%. Onion Global (NYSE:OG) +27%. Progenity (NASDAQ:PROG) +23%. China Online Education (NYSE:COE) +17%. Meten Holding (NASDAQ:METX) +16%. Achilles Therapeutics (NASDAQ:ACHL) +13%. Crown Ele...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Alzamend Neuro (NASDAQ: ALZN ) stock is on the move Thursday after getting an update from the U.S. Food and Drug Administration (FDA). Source: Shutterstock The FDA sent a letter to Alzamend Neuro detailing t...
News, Short Squeeze, Breakout and More Instantly...
AstraZeneca PLC (AZN) is expected to report $0.97 for Q2 2024 BJ's Restaurants Inc. (BJRI) is expected to report $0.49 for Q2 2024 Baker Hughes Company (BKR) is expected to report $0.49 for Q2 2024 BlueHarbor Bank (BLHK) is expected to report for Q2 2024 Betterware de Mexico S.A.P...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major de...
Investor had agreed to purchase up to $25 million of preferred shares Alzamend expects to use proceeds to further its clinical trials and working capital purposes Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical compa...